nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—OPRD1—epilepsy syndrome	0.136	0.347	CbGaD
Tapentadol—OPRM1—epilepsy syndrome	0.104	0.265	CbGaD
Tapentadol—SLC6A4—epilepsy syndrome	0.0572	0.146	CbGaD
Tapentadol—CYP2C19—epilepsy syndrome	0.0542	0.139	CbGaD
Tapentadol—UGT2B7—Carbamazepine—epilepsy syndrome	0.0443	0.128	CbGbCtD
Tapentadol—CYP2D6—epilepsy syndrome	0.0402	0.103	CbGaD
Tapentadol—UGT1A9—Propofol—epilepsy syndrome	0.0391	0.113	CbGbCtD
Tapentadol—UGT1A9—Valproic Acid—epilepsy syndrome	0.028	0.0808	CbGbCtD
Tapentadol—UGT2B7—Valproic Acid—epilepsy syndrome	0.0265	0.0765	CbGbCtD
Tapentadol—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.015	0.0433	CbGbCtD
Tapentadol—CYP2C19—Trimethadione—epilepsy syndrome	0.0139	0.0403	CbGbCtD
Tapentadol—CYP2C19—Felbamate—epilepsy syndrome	0.0139	0.0403	CbGbCtD
Tapentadol—CYP2C19—Fosphenytoin—epilepsy syndrome	0.0131	0.0379	CbGbCtD
Tapentadol—CYP2C9—Trimethadione—epilepsy syndrome	0.0116	0.0335	CbGbCtD
Tapentadol—CYP2C19—Clobazam—epilepsy syndrome	0.0114	0.0328	CbGbCtD
Tapentadol—CYP2C9—Fosphenytoin—epilepsy syndrome	0.0109	0.0315	CbGbCtD
Tapentadol—CYP2C19—Carbamazepine—epilepsy syndrome	0.00941	0.0272	CbGbCtD
Tapentadol—CYP2C19—Primidone—epilepsy syndrome	0.00878	0.0254	CbGbCtD
Tapentadol—CYP2C19—Phenytoin—epilepsy syndrome	0.00844	0.0244	CbGbCtD
Tapentadol—CYP2C19—Propofol—epilepsy syndrome	0.00787	0.0228	CbGbCtD
Tapentadol—CYP2C9—Carbamazepine—epilepsy syndrome	0.00782	0.0226	CbGbCtD
Tapentadol—CYP2C19—Phenobarbital—epilepsy syndrome	0.00752	0.0217	CbGbCtD
Tapentadol—CYP2C9—Primidone—epilepsy syndrome	0.0073	0.0211	CbGbCtD
Tapentadol—CYP2C19—Diazepam—epilepsy syndrome	0.00713	0.0206	CbGbCtD
Tapentadol—CYP2C9—Phenytoin—epilepsy syndrome	0.00702	0.0203	CbGbCtD
Tapentadol—CYP2C19—Zonisamide—epilepsy syndrome	0.00696	0.0201	CbGbCtD
Tapentadol—CYP2C9—Propofol—epilepsy syndrome	0.00654	0.0189	CbGbCtD
Tapentadol—CYP2C9—Phenobarbital—epilepsy syndrome	0.00625	0.0181	CbGbCtD
Tapentadol—CYP2D6—Propofol—epilepsy syndrome	0.00598	0.0173	CbGbCtD
Tapentadol—CYP2C9—Diazepam—epilepsy syndrome	0.00593	0.0171	CbGbCtD
Tapentadol—CYP2C19—Valproic Acid—epilepsy syndrome	0.00562	0.0163	CbGbCtD
Tapentadol—CYP2C19—Topiramate—epilepsy syndrome	0.00507	0.0147	CbGbCtD
Tapentadol—CYP2C9—Valproic Acid—epilepsy syndrome	0.00467	0.0135	CbGbCtD
Tapentadol—HTR3A—vagus nerve—epilepsy syndrome	0.00355	0.0987	CbGeAlD
Tapentadol—SLC6A2—locus ceruleus—epilepsy syndrome	0.00311	0.0865	CbGeAlD
Tapentadol—OPRM1—telencephalic ventricle—epilepsy syndrome	0.00201	0.056	CbGeAlD
Tapentadol—OPRD1—ganglion—epilepsy syndrome	0.00184	0.0511	CbGeAlD
Tapentadol—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00165	0.046	CbGeAlD
Tapentadol—HTR3A—ganglion—epilepsy syndrome	0.00137	0.038	CbGeAlD
Tapentadol—OPRM1—ganglion—epilepsy syndrome	0.00125	0.0349	CbGeAlD
Tapentadol—SLC6A4—ganglion—epilepsy syndrome	0.00104	0.029	CbGeAlD
Tapentadol—SLC6A2—ganglion—epilepsy syndrome	0.000918	0.0255	CbGeAlD
Tapentadol—SLC6A4—hindbrain—epilepsy syndrome	0.000791	0.022	CbGeAlD
Tapentadol—OPRD1—forebrain—epilepsy syndrome	0.000771	0.0215	CbGeAlD
Tapentadol—OPRK1—forebrain—epilepsy syndrome	0.00074	0.0206	CbGeAlD
Tapentadol—Edrophonium—BCHE—epilepsy syndrome	0.000734	0.41	CrCbGaD
Tapentadol—OPRD1—telencephalon—epilepsy syndrome	0.000709	0.0197	CbGeAlD
Tapentadol—Rivastigmine—BCHE—epilepsy syndrome	0.000682	0.381	CrCbGaD
Tapentadol—HTR3A—brainstem—epilepsy syndrome	0.000595	0.0165	CbGeAlD
Tapentadol—HTR3A—forebrain—epilepsy syndrome	0.000574	0.016	CbGeAlD
Tapentadol—OPRM1—brainstem—epilepsy syndrome	0.000545	0.0152	CbGeAlD
Tapentadol—HTR3A—telencephalon—epilepsy syndrome	0.000528	0.0147	CbGeAlD
Tapentadol—OPRM1—forebrain—epilepsy syndrome	0.000526	0.0146	CbGeAlD
Tapentadol—OPRM1—telencephalon—epilepsy syndrome	0.000484	0.0135	CbGeAlD
Tapentadol—SLC6A4—brainstem—epilepsy syndrome	0.000453	0.0126	CbGeAlD
Tapentadol—OPRD1—head—epilepsy syndrome	0.000442	0.0123	CbGeAlD
Tapentadol—SLC6A4—forebrain—epilepsy syndrome	0.000438	0.0122	CbGeAlD
Tapentadol—OPRK1—head—epilepsy syndrome	0.000423	0.0118	CbGeAlD
Tapentadol—OPRD1—nervous system—epilepsy syndrome	0.000419	0.0116	CbGeAlD
Tapentadol—OPRD1—central nervous system—epilepsy syndrome	0.000403	0.0112	CbGeAlD
Tapentadol—SLC6A4—telencephalon—epilepsy syndrome	0.000402	0.0112	CbGeAlD
Tapentadol—OPRK1—nervous system—epilepsy syndrome	0.000401	0.0112	CbGeAlD
Tapentadol—SLC6A2—brainstem—epilepsy syndrome	0.000399	0.0111	CbGeAlD
Tapentadol—OPRK1—central nervous system—epilepsy syndrome	0.000387	0.0108	CbGeAlD
Tapentadol—SLC6A2—forebrain—epilepsy syndrome	0.000385	0.0107	CbGeAlD
Tapentadol—CYP2D6—hindbrain—epilepsy syndrome	0.000381	0.0106	CbGeAlD
Tapentadol—OPRK1—cerebellum—epilepsy syndrome	0.000378	0.0105	CbGeAlD
Tapentadol—Rivastigmine—CYP2D6—epilepsy syndrome	0.000374	0.209	CrCbGaD
Tapentadol—SLC6A2—telencephalon—epilepsy syndrome	0.000354	0.00985	CbGeAlD
Tapentadol—OPRM1—midbrain—epilepsy syndrome	0.000347	0.00966	CbGeAlD
Tapentadol—OPRM1—spinal cord—epilepsy syndrome	0.000339	0.00943	CbGeAlD
Tapentadol—HTR3A—head—epilepsy syndrome	0.000329	0.00914	CbGeAlD
Tapentadol—OPRD1—brain—epilepsy syndrome	0.00032	0.0089	CbGeAlD
Tapentadol—HTR3A—nervous system—epilepsy syndrome	0.000312	0.00866	CbGeAlD
Tapentadol—OPRK1—brain—epilepsy syndrome	0.000307	0.00854	CbGeAlD
Tapentadol—OPRM1—head—epilepsy syndrome	0.000301	0.00838	CbGeAlD
Tapentadol—HTR3A—central nervous system—epilepsy syndrome	0.0003	0.00834	CbGeAlD
Tapentadol—SLC6A4—midbrain—epilepsy syndrome	0.000289	0.00804	CbGeAlD
Tapentadol—OPRM1—nervous system—epilepsy syndrome	0.000286	0.00794	CbGeAlD
Tapentadol—SLC6A4—spinal cord—epilepsy syndrome	0.000282	0.00784	CbGeAlD
Tapentadol—SLC6A2—medulla oblongata—epilepsy syndrome	0.000278	0.00774	CbGeAlD
Tapentadol—OPRM1—central nervous system—epilepsy syndrome	0.000275	0.00765	CbGeAlD
Tapentadol—SLC6A4—head—epilepsy syndrome	0.000251	0.00697	CbGeAlD
Tapentadol—HTR3A—brain—epilepsy syndrome	0.000238	0.00662	CbGeAlD
Tapentadol—SLC6A4—nervous system—epilepsy syndrome	0.000238	0.00661	CbGeAlD
Tapentadol—SLC6A4—central nervous system—epilepsy syndrome	0.000229	0.00636	CbGeAlD
Tapentadol—SLC6A2—head—epilepsy syndrome	0.000221	0.00614	CbGeAlD
Tapentadol—CYP2D6—brainstem—epilepsy syndrome	0.000219	0.00608	CbGeAlD
Tapentadol—OPRM1—brain—epilepsy syndrome	0.000218	0.00607	CbGeAlD
Tapentadol—CYP2D6—forebrain—epilepsy syndrome	0.000211	0.00587	CbGeAlD
Tapentadol—SLC6A2—nervous system—epilepsy syndrome	0.000209	0.00582	CbGeAlD
Tapentadol—SLC6A2—central nervous system—epilepsy syndrome	0.000201	0.0056	CbGeAlD
Tapentadol—CYP2D6—telencephalon—epilepsy syndrome	0.000194	0.00539	CbGeAlD
Tapentadol—SLC6A4—brain—epilepsy syndrome	0.000182	0.00505	CbGeAlD
Tapentadol—SLC6A2—brain—epilepsy syndrome	0.00016	0.00445	CbGeAlD
Tapentadol—CYP2D6—head—epilepsy syndrome	0.000121	0.00336	CbGeAlD
Tapentadol—CYP2D6—nervous system—epilepsy syndrome	0.000115	0.00318	CbGeAlD
Tapentadol—CYP2D6—central nervous system—epilepsy syndrome	0.00011	0.00307	CbGeAlD
Tapentadol—CYP2D6—cerebellum—epilepsy syndrome	0.000108	0.003	CbGeAlD
Tapentadol—CYP2D6—brain—epilepsy syndrome	8.75e-05	0.00243	CbGeAlD
Tapentadol—Syncope—Pregabalin—epilepsy syndrome	4.32e-05	0.000281	CcSEcCtD
Tapentadol—Rash—Fosphenytoin—epilepsy syndrome	4.3e-05	0.000279	CcSEcCtD
Tapentadol—Dermatitis—Fosphenytoin—epilepsy syndrome	4.29e-05	0.000279	CcSEcCtD
Tapentadol—Nervousness—Gabapentin—epilepsy syndrome	4.29e-05	0.000279	CcSEcCtD
Tapentadol—Asthenia—Clonazepam—epilepsy syndrome	4.28e-05	0.000278	CcSEcCtD
Tapentadol—Headache—Fosphenytoin—epilepsy syndrome	4.27e-05	0.000277	CcSEcCtD
Tapentadol—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.26e-05	0.000277	CcSEcCtD
Tapentadol—Palpitations—Pregabalin—epilepsy syndrome	4.26e-05	0.000277	CcSEcCtD
Tapentadol—Asthenia—Phenytoin—epilepsy syndrome	4.26e-05	0.000277	CcSEcCtD
Tapentadol—Nausea—Midazolam—epilepsy syndrome	4.25e-05	0.000276	CcSEcCtD
Tapentadol—Hallucination—Topiramate—epilepsy syndrome	4.25e-05	0.000276	CcSEcCtD
Tapentadol—Hypoaesthesia—Topiramate—epilepsy syndrome	4.25e-05	0.000276	CcSEcCtD
Tapentadol—Tachycardia—Valproic Acid—epilepsy syndrome	4.24e-05	0.000276	CcSEcCtD
Tapentadol—Diarrhoea—Zonisamide—epilepsy syndrome	4.24e-05	0.000275	CcSEcCtD
Tapentadol—Loss of consciousness—Pregabalin—epilepsy syndrome	4.23e-05	0.000275	CcSEcCtD
Tapentadol—Asthenia—Oxcarbazepine—epilepsy syndrome	4.23e-05	0.000275	CcSEcCtD
Tapentadol—Pruritus—Clonazepam—epilepsy syndrome	4.22e-05	0.000275	CcSEcCtD
Tapentadol—Vomiting—Vigabatrin—epilepsy syndrome	4.22e-05	0.000274	CcSEcCtD
Tapentadol—Skin disorder—Valproic Acid—epilepsy syndrome	4.22e-05	0.000274	CcSEcCtD
Tapentadol—Urinary tract disorder—Topiramate—epilepsy syndrome	4.22e-05	0.000274	CcSEcCtD
Tapentadol—Hyperhidrosis—Valproic Acid—epilepsy syndrome	4.2e-05	0.000273	CcSEcCtD
Tapentadol—Cough—Pregabalin—epilepsy syndrome	4.2e-05	0.000273	CcSEcCtD
Tapentadol—Pruritus—Phenytoin—epilepsy syndrome	4.2e-05	0.000273	CcSEcCtD
Tapentadol—Connective tissue disorder—Topiramate—epilepsy syndrome	4.19e-05	0.000273	CcSEcCtD
Tapentadol—Nausea—Levetiracetam—epilepsy syndrome	4.19e-05	0.000273	CcSEcCtD
Tapentadol—Rash—Vigabatrin—epilepsy syndrome	4.19e-05	0.000272	CcSEcCtD
Tapentadol—Dizziness—Felbamate—epilepsy syndrome	4.19e-05	0.000272	CcSEcCtD
Tapentadol—Dermatitis—Vigabatrin—epilepsy syndrome	4.18e-05	0.000272	CcSEcCtD
Tapentadol—Urethral disorder—Topiramate—epilepsy syndrome	4.18e-05	0.000272	CcSEcCtD
Tapentadol—Pruritus—Oxcarbazepine—epilepsy syndrome	4.17e-05	0.000271	CcSEcCtD
Tapentadol—Convulsion—Pregabalin—epilepsy syndrome	4.17e-05	0.000271	CcSEcCtD
Tapentadol—Hypersensitivity—Carbamazepine—epilepsy syndrome	4.17e-05	0.000271	CcSEcCtD
Tapentadol—Vision blurred—Gabapentin—epilepsy syndrome	4.16e-05	0.000271	CcSEcCtD
Tapentadol—Headache—Vigabatrin—epilepsy syndrome	4.16e-05	0.00027	CcSEcCtD
Tapentadol—Vomiting—Diazepam—epilepsy syndrome	4.16e-05	0.00027	CcSEcCtD
Tapentadol—Tremor—Gabapentin—epilepsy syndrome	4.14e-05	0.000269	CcSEcCtD
Tapentadol—Rash—Diazepam—epilepsy syndrome	4.12e-05	0.000268	CcSEcCtD
Tapentadol—Dermatitis—Diazepam—epilepsy syndrome	4.12e-05	0.000268	CcSEcCtD
Tapentadol—Visual impairment—Topiramate—epilepsy syndrome	4.11e-05	0.000267	CcSEcCtD
Tapentadol—Arthralgia—Pregabalin—epilepsy syndrome	4.1e-05	0.000266	CcSEcCtD
Tapentadol—Dizziness—Zonisamide—epilepsy syndrome	4.1e-05	0.000266	CcSEcCtD
Tapentadol—Headache—Diazepam—epilepsy syndrome	4.1e-05	0.000266	CcSEcCtD
Tapentadol—Anxiety—Pregabalin—epilepsy syndrome	4.09e-05	0.000266	CcSEcCtD
Tapentadol—Diarrhoea—Clonazepam—epilepsy syndrome	4.09e-05	0.000266	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	4.07e-05	0.000265	CcSEcCtD
Tapentadol—Hypotension—Valproic Acid—epilepsy syndrome	4.06e-05	0.000264	CcSEcCtD
Tapentadol—Asthenia—Carbamazepine—epilepsy syndrome	4.06e-05	0.000264	CcSEcCtD
Tapentadol—Agitation—Gabapentin—epilepsy syndrome	4.06e-05	0.000264	CcSEcCtD
Tapentadol—Diarrhoea—Phenytoin—epilepsy syndrome	4.06e-05	0.000264	CcSEcCtD
Tapentadol—Nausea—Fosphenytoin—epilepsy syndrome	4.05e-05	0.000263	CcSEcCtD
Tapentadol—Diarrhoea—Oxcarbazepine—epilepsy syndrome	4.04e-05	0.000262	CcSEcCtD
Tapentadol—Angioedema—Gabapentin—epilepsy syndrome	4.04e-05	0.000262	CcSEcCtD
Tapentadol—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.03e-05	0.000262	CcSEcCtD
Tapentadol—Vomiting—Felbamate—epilepsy syndrome	4.02e-05	0.000262	CcSEcCtD
Tapentadol—Dry mouth—Pregabalin—epilepsy syndrome	4.01e-05	0.000261	CcSEcCtD
Tapentadol—Pruritus—Carbamazepine—epilepsy syndrome	4.01e-05	0.00026	CcSEcCtD
Tapentadol—Rash—Felbamate—epilepsy syndrome	3.99e-05	0.000259	CcSEcCtD
Tapentadol—Eye disorder—Topiramate—epilepsy syndrome	3.99e-05	0.000259	CcSEcCtD
Tapentadol—Dermatitis—Felbamate—epilepsy syndrome	3.99e-05	0.000259	CcSEcCtD
Tapentadol—Vertigo—Gabapentin—epilepsy syndrome	3.97e-05	0.000258	CcSEcCtD
Tapentadol—Headache—Felbamate—epilepsy syndrome	3.97e-05	0.000258	CcSEcCtD
Tapentadol—Confusional state—Pregabalin—epilepsy syndrome	3.96e-05	0.000258	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.96e-05	0.000257	CcSEcCtD
Tapentadol—Cardiac disorder—Topiramate—epilepsy syndrome	3.96e-05	0.000257	CcSEcCtD
Tapentadol—Syncope—Gabapentin—epilepsy syndrome	3.96e-05	0.000257	CcSEcCtD
Tapentadol—Dizziness—Clonazepam—epilepsy syndrome	3.95e-05	0.000257	CcSEcCtD
Tapentadol—Nausea—Vigabatrin—epilepsy syndrome	3.95e-05	0.000256	CcSEcCtD
Tapentadol—Vomiting—Zonisamide—epilepsy syndrome	3.94e-05	0.000256	CcSEcCtD
Tapentadol—Insomnia—Valproic Acid—epilepsy syndrome	3.93e-05	0.000256	CcSEcCtD
Tapentadol—Oedema—Pregabalin—epilepsy syndrome	3.93e-05	0.000255	CcSEcCtD
Tapentadol—Anaphylactic shock—Pregabalin—epilepsy syndrome	3.93e-05	0.000255	CcSEcCtD
Tapentadol—Asthenia—Lamotrigine—epilepsy syndrome	3.93e-05	0.000255	CcSEcCtD
Tapentadol—Dizziness—Phenytoin—epilepsy syndrome	3.92e-05	0.000255	CcSEcCtD
Tapentadol—Rash—Zonisamide—epilepsy syndrome	3.91e-05	0.000254	CcSEcCtD
Tapentadol—Infection—Pregabalin—epilepsy syndrome	3.91e-05	0.000254	CcSEcCtD
Tapentadol—Paraesthesia—Valproic Acid—epilepsy syndrome	3.9e-05	0.000254	CcSEcCtD
Tapentadol—Palpitations—Gabapentin—epilepsy syndrome	3.9e-05	0.000254	CcSEcCtD
Tapentadol—Dermatitis—Zonisamide—epilepsy syndrome	3.9e-05	0.000254	CcSEcCtD
Tapentadol—Dizziness—Oxcarbazepine—epilepsy syndrome	3.9e-05	0.000254	CcSEcCtD
Tapentadol—Nausea—Diazepam—epilepsy syndrome	3.88e-05	0.000252	CcSEcCtD
Tapentadol—Loss of consciousness—Gabapentin—epilepsy syndrome	3.88e-05	0.000252	CcSEcCtD
Tapentadol—Headache—Zonisamide—epilepsy syndrome	3.88e-05	0.000252	CcSEcCtD
Tapentadol—Dyspnoea—Valproic Acid—epilepsy syndrome	3.88e-05	0.000252	CcSEcCtD
Tapentadol—Diarrhoea—Carbamazepine—epilepsy syndrome	3.87e-05	0.000252	CcSEcCtD
Tapentadol—Angiopathy—Topiramate—epilepsy syndrome	3.87e-05	0.000252	CcSEcCtD
Tapentadol—Pruritus—Lamotrigine—epilepsy syndrome	3.87e-05	0.000252	CcSEcCtD
Tapentadol—Shock—Pregabalin—epilepsy syndrome	3.87e-05	0.000251	CcSEcCtD
Tapentadol—Somnolence—Valproic Acid—epilepsy syndrome	3.87e-05	0.000251	CcSEcCtD
Tapentadol—Immune system disorder—Topiramate—epilepsy syndrome	3.86e-05	0.000251	CcSEcCtD
Tapentadol—Nervous system disorder—Pregabalin—epilepsy syndrome	3.85e-05	0.000251	CcSEcCtD
Tapentadol—Cough—Gabapentin—epilepsy syndrome	3.85e-05	0.00025	CcSEcCtD
Tapentadol—Mediastinal disorder—Topiramate—epilepsy syndrome	3.85e-05	0.00025	CcSEcCtD
Tapentadol—Tachycardia—Pregabalin—epilepsy syndrome	3.84e-05	0.000249	CcSEcCtD
Tapentadol—Chills—Topiramate—epilepsy syndrome	3.83e-05	0.000249	CcSEcCtD
Tapentadol—Dyspepsia—Valproic Acid—epilepsy syndrome	3.83e-05	0.000249	CcSEcCtD
Tapentadol—Convulsion—Gabapentin—epilepsy syndrome	3.83e-05	0.000249	CcSEcCtD
Tapentadol—Skin disorder—Pregabalin—epilepsy syndrome	3.82e-05	0.000248	CcSEcCtD
Tapentadol—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.8e-05	0.000247	CcSEcCtD
Tapentadol—Vomiting—Clonazepam—epilepsy syndrome	3.8e-05	0.000247	CcSEcCtD
Tapentadol—Decreased appetite—Valproic Acid—epilepsy syndrome	3.78e-05	0.000246	CcSEcCtD
Tapentadol—Vomiting—Phenytoin—epilepsy syndrome	3.77e-05	0.000245	CcSEcCtD
Tapentadol—Rash—Clonazepam—epilepsy syndrome	3.76e-05	0.000245	CcSEcCtD
Tapentadol—Dermatitis—Clonazepam—epilepsy syndrome	3.76e-05	0.000244	CcSEcCtD
Tapentadol—Arthralgia—Gabapentin—epilepsy syndrome	3.76e-05	0.000244	CcSEcCtD
Tapentadol—Nausea—Felbamate—epilepsy syndrome	3.76e-05	0.000244	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.75e-05	0.000244	CcSEcCtD
Tapentadol—Vomiting—Oxcarbazepine—epilepsy syndrome	3.75e-05	0.000244	CcSEcCtD
Tapentadol—Fatigue—Valproic Acid—epilepsy syndrome	3.75e-05	0.000244	CcSEcCtD
Tapentadol—Anxiety—Gabapentin—epilepsy syndrome	3.75e-05	0.000244	CcSEcCtD
Tapentadol—Dizziness—Carbamazepine—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Diarrhoea—Lamotrigine—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Headache—Clonazepam—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Rash—Phenytoin—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Mental disorder—Topiramate—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Dermatitis—Phenytoin—epilepsy syndrome	3.74e-05	0.000243	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.73e-05	0.000243	CcSEcCtD
Tapentadol—Rash—Oxcarbazepine—epilepsy syndrome	3.72e-05	0.000242	CcSEcCtD
Tapentadol—Constipation—Valproic Acid—epilepsy syndrome	3.72e-05	0.000242	CcSEcCtD
Tapentadol—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.72e-05	0.000242	CcSEcCtD
Tapentadol—Headache—Phenytoin—epilepsy syndrome	3.72e-05	0.000241	CcSEcCtD
Tapentadol—Malnutrition—Topiramate—epilepsy syndrome	3.72e-05	0.000241	CcSEcCtD
Tapentadol—Headache—Oxcarbazepine—epilepsy syndrome	3.7e-05	0.00024	CcSEcCtD
Tapentadol—Nausea—Zonisamide—epilepsy syndrome	3.68e-05	0.000239	CcSEcCtD
Tapentadol—Dry mouth—Gabapentin—epilepsy syndrome	3.68e-05	0.000239	CcSEcCtD
Tapentadol—Hypotension—Pregabalin—epilepsy syndrome	3.67e-05	0.000239	CcSEcCtD
Tapentadol—Tension—Topiramate—epilepsy syndrome	3.65e-05	0.000237	CcSEcCtD
Tapentadol—Confusional state—Gabapentin—epilepsy syndrome	3.63e-05	0.000236	CcSEcCtD
Tapentadol—Dizziness—Lamotrigine—epilepsy syndrome	3.62e-05	0.000235	CcSEcCtD
Tapentadol—Nervousness—Topiramate—epilepsy syndrome	3.61e-05	0.000235	CcSEcCtD
Tapentadol—Anaphylactic shock—Gabapentin—epilepsy syndrome	3.6e-05	0.000234	CcSEcCtD
Tapentadol—Oedema—Gabapentin—epilepsy syndrome	3.6e-05	0.000234	CcSEcCtD
Tapentadol—Vomiting—Carbamazepine—epilepsy syndrome	3.6e-05	0.000234	CcSEcCtD
Tapentadol—Feeling abnormal—Valproic Acid—epilepsy syndrome	3.58e-05	0.000233	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.58e-05	0.000233	CcSEcCtD
Tapentadol—Infection—Gabapentin—epilepsy syndrome	3.58e-05	0.000233	CcSEcCtD
Tapentadol—Rash—Carbamazepine—epilepsy syndrome	3.57e-05	0.000232	CcSEcCtD
Tapentadol—Dermatitis—Carbamazepine—epilepsy syndrome	3.57e-05	0.000232	CcSEcCtD
Tapentadol—Insomnia—Pregabalin—epilepsy syndrome	3.56e-05	0.000231	CcSEcCtD
Tapentadol—Nausea—Clonazepam—epilepsy syndrome	3.55e-05	0.000231	CcSEcCtD
Tapentadol—Headache—Carbamazepine—epilepsy syndrome	3.55e-05	0.000231	CcSEcCtD
Tapentadol—Shock—Gabapentin—epilepsy syndrome	3.55e-05	0.00023	CcSEcCtD
Tapentadol—Nervous system disorder—Gabapentin—epilepsy syndrome	3.53e-05	0.00023	CcSEcCtD
Tapentadol—Paraesthesia—Pregabalin—epilepsy syndrome	3.53e-05	0.000229	CcSEcCtD
Tapentadol—Nausea—Phenytoin—epilepsy syndrome	3.52e-05	0.000229	CcSEcCtD
Tapentadol—Tachycardia—Gabapentin—epilepsy syndrome	3.52e-05	0.000229	CcSEcCtD
Tapentadol—Dyspnoea—Pregabalin—epilepsy syndrome	3.5e-05	0.000228	CcSEcCtD
Tapentadol—Nausea—Oxcarbazepine—epilepsy syndrome	3.5e-05	0.000228	CcSEcCtD
Tapentadol—Vision blurred—Topiramate—epilepsy syndrome	3.5e-05	0.000228	CcSEcCtD
Tapentadol—Skin disorder—Gabapentin—epilepsy syndrome	3.5e-05	0.000228	CcSEcCtD
Tapentadol—Somnolence—Pregabalin—epilepsy syndrome	3.49e-05	0.000227	CcSEcCtD
Tapentadol—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.48e-05	0.000226	CcSEcCtD
Tapentadol—Tremor—Topiramate—epilepsy syndrome	3.48e-05	0.000226	CcSEcCtD
Tapentadol—Vomiting—Lamotrigine—epilepsy syndrome	3.48e-05	0.000226	CcSEcCtD
Tapentadol—Urticaria—Valproic Acid—epilepsy syndrome	3.45e-05	0.000224	CcSEcCtD
Tapentadol—Rash—Lamotrigine—epilepsy syndrome	3.45e-05	0.000224	CcSEcCtD
Tapentadol—Dermatitis—Lamotrigine—epilepsy syndrome	3.45e-05	0.000224	CcSEcCtD
Tapentadol—Headache—Lamotrigine—epilepsy syndrome	3.43e-05	0.000223	CcSEcCtD
Tapentadol—Decreased appetite—Pregabalin—epilepsy syndrome	3.42e-05	0.000222	CcSEcCtD
Tapentadol—Agitation—Topiramate—epilepsy syndrome	3.41e-05	0.000222	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.39e-05	0.000221	CcSEcCtD
Tapentadol—Fatigue—Pregabalin—epilepsy syndrome	3.39e-05	0.00022	CcSEcCtD
Tapentadol—Hypotension—Gabapentin—epilepsy syndrome	3.37e-05	0.000219	CcSEcCtD
Tapentadol—Nausea—Carbamazepine—epilepsy syndrome	3.36e-05	0.000219	CcSEcCtD
Tapentadol—Constipation—Pregabalin—epilepsy syndrome	3.36e-05	0.000218	CcSEcCtD
Tapentadol—Vertigo—Topiramate—epilepsy syndrome	3.34e-05	0.000217	CcSEcCtD
Tapentadol—Syncope—Topiramate—epilepsy syndrome	3.33e-05	0.000217	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	3.28e-05	0.000213	CcSEcCtD
Tapentadol—Palpitations—Topiramate—epilepsy syndrome	3.28e-05	0.000213	CcSEcCtD
Tapentadol—Loss of consciousness—Topiramate—epilepsy syndrome	3.27e-05	0.000212	CcSEcCtD
Tapentadol—Insomnia—Gabapentin—epilepsy syndrome	3.26e-05	0.000212	CcSEcCtD
Tapentadol—Nausea—Lamotrigine—epilepsy syndrome	3.25e-05	0.000211	CcSEcCtD
Tapentadol—Cough—Topiramate—epilepsy syndrome	3.24e-05	0.000211	CcSEcCtD
Tapentadol—Feeling abnormal—Pregabalin—epilepsy syndrome	3.24e-05	0.000211	CcSEcCtD
Tapentadol—Paraesthesia—Gabapentin—epilepsy syndrome	3.24e-05	0.00021	CcSEcCtD
Tapentadol—Convulsion—Topiramate—epilepsy syndrome	3.22e-05	0.000209	CcSEcCtD
Tapentadol—Dyspnoea—Gabapentin—epilepsy syndrome	3.21e-05	0.000209	CcSEcCtD
Tapentadol—Somnolence—Gabapentin—epilepsy syndrome	3.2e-05	0.000208	CcSEcCtD
Tapentadol—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.2e-05	0.000208	CcSEcCtD
Tapentadol—Dyspepsia—Gabapentin—epilepsy syndrome	3.17e-05	0.000206	CcSEcCtD
Tapentadol—Arthralgia—Topiramate—epilepsy syndrome	3.16e-05	0.000206	CcSEcCtD
Tapentadol—Anxiety—Topiramate—epilepsy syndrome	3.15e-05	0.000205	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.14e-05	0.000204	CcSEcCtD
Tapentadol—Decreased appetite—Gabapentin—epilepsy syndrome	3.13e-05	0.000204	CcSEcCtD
Tapentadol—Urticaria—Pregabalin—epilepsy syndrome	3.12e-05	0.000203	CcSEcCtD
Tapentadol—Asthenia—Valproic Acid—epilepsy syndrome	3.12e-05	0.000203	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.11e-05	0.000202	CcSEcCtD
Tapentadol—Fatigue—Gabapentin—epilepsy syndrome	3.11e-05	0.000202	CcSEcCtD
Tapentadol—Dry mouth—Topiramate—epilepsy syndrome	3.09e-05	0.000201	CcSEcCtD
Tapentadol—Constipation—Gabapentin—epilepsy syndrome	3.08e-05	0.0002	CcSEcCtD
Tapentadol—Pruritus—Valproic Acid—epilepsy syndrome	3.08e-05	0.0002	CcSEcCtD
Tapentadol—Confusional state—Topiramate—epilepsy syndrome	3.06e-05	0.000199	CcSEcCtD
Tapentadol—Oedema—Topiramate—epilepsy syndrome	3.03e-05	0.000197	CcSEcCtD
Tapentadol—Infection—Topiramate—epilepsy syndrome	3.01e-05	0.000196	CcSEcCtD
Tapentadol—Shock—Topiramate—epilepsy syndrome	2.98e-05	0.000194	CcSEcCtD
Tapentadol—Diarrhoea—Valproic Acid—epilepsy syndrome	2.97e-05	0.000193	CcSEcCtD
Tapentadol—Nervous system disorder—Topiramate—epilepsy syndrome	2.97e-05	0.000193	CcSEcCtD
Tapentadol—Feeling abnormal—Gabapentin—epilepsy syndrome	2.97e-05	0.000193	CcSEcCtD
Tapentadol—Tachycardia—Topiramate—epilepsy syndrome	2.96e-05	0.000192	CcSEcCtD
Tapentadol—Skin disorder—Topiramate—epilepsy syndrome	2.95e-05	0.000191	CcSEcCtD
Tapentadol—Hyperhidrosis—Topiramate—epilepsy syndrome	2.93e-05	0.000191	CcSEcCtD
Tapentadol—Hypersensitivity—Pregabalin—epilepsy syndrome	2.9e-05	0.000188	CcSEcCtD
Tapentadol—Dizziness—Valproic Acid—epilepsy syndrome	2.88e-05	0.000187	CcSEcCtD
Tapentadol—Urticaria—Gabapentin—epilepsy syndrome	2.86e-05	0.000186	CcSEcCtD
Tapentadol—Hypotension—Topiramate—epilepsy syndrome	2.83e-05	0.000184	CcSEcCtD
Tapentadol—Asthenia—Pregabalin—epilepsy syndrome	2.82e-05	0.000183	CcSEcCtD
Tapentadol—Pruritus—Pregabalin—epilepsy syndrome	2.78e-05	0.000181	CcSEcCtD
Tapentadol—Vomiting—Valproic Acid—epilepsy syndrome	2.76e-05	0.00018	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.76e-05	0.00018	CcSEcCtD
Tapentadol—Insomnia—Topiramate—epilepsy syndrome	2.74e-05	0.000178	CcSEcCtD
Tapentadol—Rash—Valproic Acid—epilepsy syndrome	2.74e-05	0.000178	CcSEcCtD
Tapentadol—Dermatitis—Valproic Acid—epilepsy syndrome	2.74e-05	0.000178	CcSEcCtD
Tapentadol—Headache—Valproic Acid—epilepsy syndrome	2.72e-05	0.000177	CcSEcCtD
Tapentadol—Paraesthesia—Topiramate—epilepsy syndrome	2.72e-05	0.000177	CcSEcCtD
Tapentadol—Dyspnoea—Topiramate—epilepsy syndrome	2.7e-05	0.000176	CcSEcCtD
Tapentadol—Somnolence—Topiramate—epilepsy syndrome	2.7e-05	0.000175	CcSEcCtD
Tapentadol—Diarrhoea—Pregabalin—epilepsy syndrome	2.69e-05	0.000175	CcSEcCtD
Tapentadol—Dyspepsia—Topiramate—epilepsy syndrome	2.67e-05	0.000173	CcSEcCtD
Tapentadol—Hypersensitivity—Gabapentin—epilepsy syndrome	2.66e-05	0.000173	CcSEcCtD
Tapentadol—Decreased appetite—Topiramate—epilepsy syndrome	2.64e-05	0.000171	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.62e-05	0.00017	CcSEcCtD
Tapentadol—Fatigue—Topiramate—epilepsy syndrome	2.61e-05	0.00017	CcSEcCtD
Tapentadol—Dizziness—Pregabalin—epilepsy syndrome	2.6e-05	0.000169	CcSEcCtD
Tapentadol—Constipation—Topiramate—epilepsy syndrome	2.59e-05	0.000169	CcSEcCtD
Tapentadol—Asthenia—Gabapentin—epilepsy syndrome	2.59e-05	0.000168	CcSEcCtD
Tapentadol—Nausea—Valproic Acid—epilepsy syndrome	2.58e-05	0.000168	CcSEcCtD
Tapentadol—Pruritus—Gabapentin—epilepsy syndrome	2.55e-05	0.000166	CcSEcCtD
Tapentadol—Vomiting—Pregabalin—epilepsy syndrome	2.5e-05	0.000162	CcSEcCtD
Tapentadol—Feeling abnormal—Topiramate—epilepsy syndrome	2.5e-05	0.000162	CcSEcCtD
Tapentadol—Rash—Pregabalin—epilepsy syndrome	2.48e-05	0.000161	CcSEcCtD
Tapentadol—Dermatitis—Pregabalin—epilepsy syndrome	2.48e-05	0.000161	CcSEcCtD
Tapentadol—Diarrhoea—Gabapentin—epilepsy syndrome	2.47e-05	0.00016	CcSEcCtD
Tapentadol—Headache—Pregabalin—epilepsy syndrome	2.46e-05	0.00016	CcSEcCtD
Tapentadol—Urticaria—Topiramate—epilepsy syndrome	2.41e-05	0.000157	CcSEcCtD
Tapentadol—Dizziness—Gabapentin—epilepsy syndrome	2.38e-05	0.000155	CcSEcCtD
Tapentadol—Nausea—Pregabalin—epilepsy syndrome	2.33e-05	0.000152	CcSEcCtD
Tapentadol—Vomiting—Gabapentin—epilepsy syndrome	2.29e-05	0.000149	CcSEcCtD
Tapentadol—Rash—Gabapentin—epilepsy syndrome	2.27e-05	0.000148	CcSEcCtD
Tapentadol—Dermatitis—Gabapentin—epilepsy syndrome	2.27e-05	0.000148	CcSEcCtD
Tapentadol—Headache—Gabapentin—epilepsy syndrome	2.26e-05	0.000147	CcSEcCtD
Tapentadol—Hypersensitivity—Topiramate—epilepsy syndrome	2.23e-05	0.000145	CcSEcCtD
Tapentadol—Asthenia—Topiramate—epilepsy syndrome	2.18e-05	0.000141	CcSEcCtD
Tapentadol—Pruritus—Topiramate—epilepsy syndrome	2.15e-05	0.000139	CcSEcCtD
Tapentadol—Nausea—Gabapentin—epilepsy syndrome	2.14e-05	0.000139	CcSEcCtD
Tapentadol—Diarrhoea—Topiramate—epilepsy syndrome	2.07e-05	0.000135	CcSEcCtD
Tapentadol—Dizziness—Topiramate—epilepsy syndrome	2.01e-05	0.00013	CcSEcCtD
Tapentadol—Vomiting—Topiramate—epilepsy syndrome	1.93e-05	0.000125	CcSEcCtD
Tapentadol—Rash—Topiramate—epilepsy syndrome	1.91e-05	0.000124	CcSEcCtD
Tapentadol—Dermatitis—Topiramate—epilepsy syndrome	1.91e-05	0.000124	CcSEcCtD
Tapentadol—Headache—Topiramate—epilepsy syndrome	1.9e-05	0.000123	CcSEcCtD
Tapentadol—Nausea—Topiramate—epilepsy syndrome	1.8e-05	0.000117	CcSEcCtD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	5.38e-06	7.55e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6ST—epilepsy syndrome	5.38e-06	7.54e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CACNA1A—epilepsy syndrome	5.33e-06	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDH7A1—epilepsy syndrome	5.33e-06	7.49e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUNB—epilepsy syndrome	5.32e-06	7.47e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CNR1—epilepsy syndrome	5.32e-06	7.47e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCR5—epilepsy syndrome	5.32e-06	7.46e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PLCB1—epilepsy syndrome	5.3e-06	7.44e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—STXBP1—epilepsy syndrome	5.28e-06	7.41e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—STXBP1—epilepsy syndrome	5.23e-06	7.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ST3GAL3—epilepsy syndrome	5.22e-06	7.32e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—S100B—epilepsy syndrome	5.21e-06	7.31e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HTR2A—epilepsy syndrome	5.2e-06	7.3e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HTR7—epilepsy syndrome	5.19e-06	7.29e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SOCS3—epilepsy syndrome	5.16e-06	7.24e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDC42—epilepsy syndrome	5.15e-06	7.23e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NT5E—epilepsy syndrome	5.14e-06	7.22e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALAD—epilepsy syndrome	5.14e-06	7.22e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADSL—epilepsy syndrome	5.11e-06	7.18e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALAD—epilepsy syndrome	5.1e-06	7.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NT5E—epilepsy syndrome	5.1e-06	7.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HBEGF—epilepsy syndrome	5.04e-06	7.07e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PRKCB—epilepsy syndrome	5.02e-06	7.05e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GLUL—epilepsy syndrome	5.02e-06	7.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC1—epilepsy syndrome	5.01e-06	7.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTK2B—epilepsy syndrome	5.01e-06	7.03e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GPX1—epilepsy syndrome	5.01e-06	7.02e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AVP—epilepsy syndrome	4.99e-06	7e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT3—epilepsy syndrome	4.95e-06	6.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AGT—epilepsy syndrome	4.94e-06	6.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CACNA1D—epilepsy syndrome	4.92e-06	6.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—POMC—epilepsy syndrome	4.92e-06	6.9e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	4.91e-06	6.88e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	4.91e-06	6.88e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCR2—epilepsy syndrome	4.88e-06	6.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SST—epilepsy syndrome	4.88e-06	6.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NTRK2—epilepsy syndrome	4.88e-06	6.84e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CACNA1A—epilepsy syndrome	4.86e-06	6.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDH7A1—epilepsy syndrome	4.86e-06	6.82e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADAM10—epilepsy syndrome	4.83e-06	6.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—DUSP6—epilepsy syndrome	4.83e-06	6.78e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL2—epilepsy syndrome	4.81e-06	6.75e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	4.8e-06	6.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRA2A—epilepsy syndrome	4.77e-06	6.69e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ST3GAL3—epilepsy syndrome	4.76e-06	6.68e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PLAT—epilepsy syndrome	4.75e-06	6.67e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HES1—epilepsy syndrome	4.71e-06	6.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADSL—epilepsy syndrome	4.7e-06	6.6e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADSL—epilepsy syndrome	4.66e-06	6.54e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GLUL—epilepsy syndrome	4.61e-06	6.47e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TXNRD1—epilepsy syndrome	4.6e-06	6.46e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FYN—epilepsy syndrome	4.58e-06	6.43e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL12—epilepsy syndrome	4.58e-06	6.43e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BDKRB2—epilepsy syndrome	4.58e-06	6.43e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—POMC—epilepsy syndrome	4.58e-06	6.42e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GLUL—epilepsy syndrome	4.57e-06	6.42e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—S100B—epilepsy syndrome	4.57e-06	6.41e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—H2AFX—epilepsy syndrome	4.57e-06	6.41e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PRKCB—epilepsy syndrome	4.56e-06	6.4e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MEF2C—epilepsy syndrome	4.56e-06	6.4e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HMOX1—epilepsy syndrome	4.56e-06	6.4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6ST—epilepsy syndrome	4.54e-06	6.38e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	4.53e-06	6.35e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SOCS3—epilepsy syndrome	4.53e-06	6.35e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDC42—epilepsy syndrome	4.52e-06	6.34e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUNB—epilepsy syndrome	4.5e-06	6.31e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CNR1—epilepsy syndrome	4.5e-06	6.31e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CAT—epilepsy syndrome	4.5e-06	6.31e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CACNA1D—epilepsy syndrome	4.49e-06	6.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PLCB1—epilepsy syndrome	4.48e-06	6.29e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AQP1—epilepsy syndrome	4.47e-06	6.27e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—YWHAZ—epilepsy syndrome	4.41e-06	6.18e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AGT—epilepsy syndrome	4.39e-06	6.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HTR7—epilepsy syndrome	4.39e-06	6.16e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ABCB1—epilepsy syndrome	4.38e-06	6.14e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AVP—epilepsy syndrome	4.37e-06	6.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NGF—epilepsy syndrome	4.36e-06	6.11e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—APOE—epilepsy syndrome	4.3e-06	6.04e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	4.29e-06	6.02e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HBEGF—epilepsy syndrome	4.26e-06	5.98e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCR5—epilepsy syndrome	4.24e-06	5.95e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	4.24e-06	5.94e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TXNRD1—epilepsy syndrome	4.2e-06	5.89e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT3—epilepsy syndrome	4.18e-06	5.87e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—POMC—epilepsy syndrome	4.16e-06	5.83e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HTR2A—epilepsy syndrome	4.15e-06	5.82e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HES1—epilepsy syndrome	4.13e-06	5.8e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AQP1—epilepsy syndrome	4.11e-06	5.77e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADAM10—epilepsy syndrome	4.09e-06	5.73e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AQP1—epilepsy syndrome	4.08e-06	5.72e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GPX1—epilepsy syndrome	4.07e-06	5.71e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL2—epilepsy syndrome	4.07e-06	5.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—KCNJ11—epilepsy syndrome	4.04e-06	5.67e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CHRM3—epilepsy syndrome	4.04e-06	5.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FYN—epilepsy syndrome	4.02e-06	5.64e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—H2AFX—epilepsy syndrome	4.01e-06	5.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MEF2C—epilepsy syndrome	4e-06	5.61e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TSC2—epilepsy syndrome	3.94e-06	5.53e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AGT—epilepsy syndrome	3.94e-06	5.52e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	3.91e-06	5.49e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—YWHAZ—epilepsy syndrome	3.86e-06	5.42e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—S100B—epilepsy syndrome	3.86e-06	5.42e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APOE—epilepsy syndrome	3.86e-06	5.41e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SOCS3—epilepsy syndrome	3.83e-06	5.37e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NGF—epilepsy syndrome	3.82e-06	5.36e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDC42—epilepsy syndrome	3.82e-06	5.35e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KDR—epilepsy syndrome	3.78e-06	5.3e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	3.76e-06	5.28e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	3.72e-06	5.22e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	3.72e-06	5.22e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCR5—epilepsy syndrome	3.72e-06	5.22e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—POMC—epilepsy syndrome	3.7e-06	5.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AVP—epilepsy syndrome	3.69e-06	5.18e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	3.69e-06	5.18e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CHRM3—epilepsy syndrome	3.69e-06	5.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—KCNJ11—epilepsy syndrome	3.69e-06	5.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HTR2A—epilepsy syndrome	3.64e-06	5.1e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PRKCB—epilepsy syndrome	3.64e-06	5.1e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6ST—epilepsy syndrome	3.62e-06	5.08e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AGT—epilepsy syndrome	3.57e-06	5.01e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOE—epilepsy syndrome	3.5e-06	4.9e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HES1—epilepsy syndrome	3.49e-06	4.9e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TSC2—epilepsy syndrome	3.46e-06	4.85e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGT—epilepsy syndrome	3.45e-06	4.84e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	3.43e-06	4.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FYN—epilepsy syndrome	3.4e-06	4.77e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—H2AFX—epilepsy syndrome	3.39e-06	4.75e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOE—epilepsy syndrome	3.38e-06	4.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MEF2C—epilepsy syndrome	3.38e-06	4.74e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—epilepsy syndrome	3.37e-06	4.73e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	3.36e-06	4.72e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—POMC—epilepsy syndrome	3.31e-06	4.65e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KDR—epilepsy syndrome	3.31e-06	4.65e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	3.3e-06	4.62e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	3.27e-06	4.58e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL2—epilepsy syndrome	3.24e-06	4.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NGF—epilepsy syndrome	3.23e-06	4.53e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	3.19e-06	4.48e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PRKCB—epilepsy syndrome	3.19e-06	4.47e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6ST—epilepsy syndrome	3.18e-06	4.46e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	3.17e-06	4.45e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCR5—epilepsy syndrome	3.14e-06	4.41e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HTR2A—epilepsy syndrome	3.07e-06	4.31e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	3.03e-06	4.25e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	3.01e-06	4.22e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—POMC—epilepsy syndrome	3e-06	4.21e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	2.95e-06	4.14e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—epilepsy syndrome	2.95e-06	4.14e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	2.94e-06	4.12e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGF2—epilepsy syndrome	2.93e-06	4.11e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	2.93e-06	4.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC2—epilepsy syndrome	2.92e-06	4.1e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGT—epilepsy syndrome	2.92e-06	4.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	2.91e-06	4.08e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—POMC—epilepsy syndrome	2.91e-06	4.08e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.89e-06	4.05e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.89e-06	4.05e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	2.88e-06	4.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOE—epilepsy syndrome	2.86e-06	4.01e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL2—epilepsy syndrome	2.84e-06	3.99e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—epilepsy syndrome	2.8e-06	3.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	2.74e-06	3.85e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—epilepsy syndrome	2.74e-06	3.84e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BCHE—epilepsy syndrome	2.73e-06	3.83e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RELA—epilepsy syndrome	2.72e-06	3.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKCB—epilepsy syndrome	2.7e-06	3.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6ST—epilepsy syndrome	2.68e-06	3.77e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—epilepsy syndrome	2.67e-06	3.74e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.63e-06	3.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	2.63e-06	3.69e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	2.61e-06	3.66e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	2.58e-06	3.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGF2—epilepsy syndrome	2.57e-06	3.6e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TH—epilepsy syndrome	2.57e-06	3.6e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.53e-06	3.55e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	2.52e-06	3.54e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BCHE—epilepsy syndrome	2.51e-06	3.52e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	2.5e-06	3.51e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BCHE—epilepsy syndrome	2.49e-06	3.49e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	2.48e-06	3.47e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—POMC—epilepsy syndrome	2.46e-06	3.45e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—epilepsy syndrome	2.45e-06	3.44e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL2—epilepsy syndrome	2.4e-06	3.37e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	2.4e-06	3.36e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—epilepsy syndrome	2.4e-06	3.36e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RELA—epilepsy syndrome	2.38e-06	3.35e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—epilepsy syndrome	2.38e-06	3.34e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	2.38e-06	3.33e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	2.37e-06	3.33e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TH—epilepsy syndrome	2.36e-06	3.31e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	2.35e-06	3.3e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TH—epilepsy syndrome	2.34e-06	3.28e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—epilepsy syndrome	2.34e-06	3.28e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—epilepsy syndrome	2.32e-06	3.25e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.3e-06	3.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—epilepsy syndrome	2.25e-06	3.15e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGF2—epilepsy syndrome	2.17e-06	3.05e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—epilepsy syndrome	2.17e-06	3.05e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—epilepsy syndrome	2.15e-06	3.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	2.14e-06	3.01e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—epilepsy syndrome	2.14e-06	3e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAT—epilepsy syndrome	2.11e-06	2.97e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—epilepsy syndrome	2.09e-06	2.93e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—epilepsy syndrome	2.08e-06	2.92e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	2.06e-06	2.89e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—epilepsy syndrome	2.03e-06	2.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RELA—epilepsy syndrome	2.02e-06	2.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—epilepsy syndrome	1.98e-06	2.77e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—epilepsy syndrome	1.97e-06	2.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.97e-06	2.77e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	1.95e-06	2.74e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.94e-06	2.73e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAT—epilepsy syndrome	1.93e-06	2.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—epilepsy syndrome	1.91e-06	2.68e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.89e-06	2.65e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	1.88e-06	2.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—epilepsy syndrome	1.87e-06	2.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.83e-06	2.57e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.83e-06	2.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—epilepsy syndrome	1.82e-06	2.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—epilepsy syndrome	1.77e-06	2.48e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.76e-06	2.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—epilepsy syndrome	1.74e-06	2.45e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—epilepsy syndrome	1.72e-06	2.41e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGT—epilepsy syndrome	1.68e-06	2.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—epilepsy syndrome	1.67e-06	2.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOE—epilepsy syndrome	1.64e-06	2.31e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—epilepsy syndrome	1.58e-06	2.22e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—epilepsy syndrome	1.54e-06	2.16e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.54e-06	2.16e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGT—epilepsy syndrome	1.53e-06	2.15e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOE—epilepsy syndrome	1.51e-06	2.12e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOE—epilepsy syndrome	1.5e-06	2.1e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—epilepsy syndrome	1.48e-06	2.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—POMC—epilepsy syndrome	1.41e-06	1.98e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—epilepsy syndrome	1.33e-06	1.86e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—POMC—epilepsy syndrome	1.3e-06	1.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—POMC—epilepsy syndrome	1.29e-06	1.81e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—epilepsy syndrome	1.29e-06	1.81e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—epilepsy syndrome	1.2e-06	1.69e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—epilepsy syndrome	1.18e-06	1.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—epilepsy syndrome	1.17e-06	1.65e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—epilepsy syndrome	1.16e-06	1.63e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	1.13e-06	1.58e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	1.04e-06	1.45e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	1.03e-06	1.44e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—epilepsy syndrome	9.84e-07	1.38e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—epilepsy syndrome	5.66e-07	7.94e-06	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—epilepsy syndrome	5.2e-07	7.3e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—epilepsy syndrome	5.16e-07	7.24e-06	CbGpPWpGaD
